REMARKS

Claim 1 has been amended to include SEQ ID numbers which were inadvertently omitted from applicant's Supplementary Response dated March 11, 2004. No new matter has been added. Hence, as the Examiner graciously acknowledged in the Office Communication mailed May 21, 2004, no substitute CRF or paper copy of the sequence listing need be submitted.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 220002054822. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated:

June 16, 2004

By:

Kate H. Murashige


Registration No. 29,959

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5112 Facsimile: (858) 720-5125



Please find below and/or attached an Office communication concerning this application or proceeding.

Cong to Save 5/24'
5-26-04



CONTROL NO.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trad. ark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

PATENT STATE

APPLICATION NO./ | FILING DATE | FIF

FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

ART UNIT PAPER

20040519

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. The application fails to comply with at least 37 CFR 1.181(d). The claims submitted 3/15/04 recite amino acid sequences without accompanying sequence identifiers. Applicant should review the entire specification including drawings and claims to ensure that the application fully complies with the sequence rules. If, to comply with the sequence rules, applicant has only to provide unidentified sequences with sequence identifiers of record, then no substitute CRF or paper copy of the sequence listing need be submitted.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

-Not ATTACHED

SEAN MCGARRY PRIMARY EXAMINER

1635



Examiner Sean McGarry

COUNT SHEET FOR SEQUENCE CASES

Serial No. <u>09/836,073</u>	AE
Mark only one space below	Date of Count
	(CRFN) (CRF is unreadable; use CRF Diskette Problem Report)
X	(CRFD) (CRF does not comply; use Notice to Comply)
	(CRFR) (CRF required but none submitted; use Notice to Comply)
	(bona fide) (second or subsequent letter to applicant reporting bona fide attempt to comply; use Notice to Comply and send copy of RSL)
	(non bona fide) (second or subsequent letter to applicant reporting non-bona fide attempt to comply; use Notice to Comply and send copy of RSL)

GAU 1635